Clinical Report: Ensuring Fairness in Genomic Screening Across Populations

Overview

Sonawane et al. highlight disparities in genomic testing uptake among underserved populations in South Carolina. Their initiative aims to provide free DNA tests to 100,000 individuals.

Background

Equitable representation in health programs is crucial for addressing healthcare disparities, particularly among socioeconomically disadvantaged and racially diverse groups. The implementation of genomic screening policies has not achieved adequate participation from these populations.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The South Carolina Medicaid BRCA testing policy was expanded to include whole-exome and whole-genome sequencing.
• Low uptake of genomic tests was observed, particularly in rural and underserved populations.
• Community-based collection events were organized to enhance participation.
• Participants with relevant genetic variants were offered free genetic counseling and follow-up care options.
• An informatics infrastructure was developed to monitor program enrollment and screening test completion.

Clinical Implications

Healthcare providers should be aware of the disparities in genomic testing access.

Conclusion

Further research is needed to evaluate the effectiveness and outcomes of the initiative.

Related Resources & Content

1. Sonawane et al., JAMA Network Open, 2023 -- Ensuring Fairness in Genomic Screening Across Populations
2. the pathologist — Social Responsibility in Molecular Medicine
3. The ASCO Post — Should Restrictions on Genetic Testing Be Loosened?
4. Whole Genome Sequencing in Recurrent Glioblastoma: Issues Surrounding Informed Consent and Data Sharing
5. Geographic and Social Equity in Population-Wide Genomic Screening
6. Social Responsibility in Molecular Medicine
7. Should Restrictions on Genetic Testing Be Loosened?
8. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026 - PubMed
9. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline | Journal of Clinical Oncology
10. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline | Journal of Clinical Oncology
11. Quality ID #507: Appropriate Germline Testing for Ovarian Cancer Patients
12. Ethical Considerations for Genetic Testing and Counseling in Obstetrics and Gynecology | ACOG
13. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | New England Journal of Medicine
14. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer - PMC
15. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial | Journal of Clinical Oncology
16. Equity in Population-Wide Genomic Screening | Cancer Screening, Prevention, Control | JAMA Network Open | JAMA Network
17. Geographic and Social Equity in Population-Wide Genomic Screening | Cancer Screening, Prevention, Control | JAMA Network Open | JAMA Network
18. NIH's All of Us Research Program is now the largest integrated genomics and health database in the world  | National Institutes of Health (NIH)
19. Genetic ancestry and population structure in the All of Us Research Program cohort | Nature Communications
20. Evaluating Outcomes of Genomic Screening